Skip to NavigationSkip to content

Johnson & Johnson

Janssen sales follow J&J’s downward trend

J&J front
J&J's overall and pharma sales are down year on year

Strong sales of its new hepatitis C treatment Olysio were not enough to stop a slump in profits at J&J’s pharmaceutical arm Janssen.

Janssen’s sales fell to $7.9 billion in the second quarter of 2015, a decrease of 6.6% compared to the year before, according to the health care giant’s latest financial results.

The firm says it has been hit in the last year by the effects of a negative currency impact. Excluding the net impact of acquisitions and divestments, worldwide sales increased 1.5%, domestic sales decreased 0.6% and international sales rose by 3.9%.

J&J profits down in Q3

J&J image

Johnson & Johnson has reported a 6.5% year-on-year sales increase to $17.1 billion in the third quarter of 2012, a rise due in large part to buying surgical equipment manufacturer Synthes.

But the $21.3 billion acquisition - the subject of a $241 million charge in this quarter - helped in having the opposite effect on profit, which was down 7.3% on the same period in 2011 to $2.97 billion.

This was part of a $553 million overall charge which included costs connected to the abondonment of Phase III drug bapineuzumab IV.

Pharma creates non-profit R&D organisation

Ten biopharma companies have formed TransCelerate BioPharma Inc, a not-for-profit organisation using money and personnel from each firm, with a mission to speed up the development of new medicines.

The firms involved are: Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche’s Genentech and Sanofi.

The cost of R&D and a move away from blockbusters towards personalised medicines has seen manufacturers seek new models for finding and developing drugs in recent years.

J&J buys into Genmab cancer drug

Danish biotech company Genmab has sold the worldwide rights for one of its cancer drugs to Johnson & Johnson-owned Janssen Biotech.

Janssen will pay $55 million upfront for daratumumab and J&J Development Corporation will invest a further $80 million in 5.4 million new Genmab shares, giving it a 10.7% equity stake in the company.

The deal, when potential development, regulatory and sales milestone payments and double digit royalties are taken into account, could top $1.1 billion, Genmab says.

Sheri McCoy resigns from Johnson & Johnson

Published on: 10/04/12

Johnson & Johnson has announced that Sheri McCoy, vice chairman of the executive committee, will leave the company on April 18, to join Avon Products as it new chief executive. 

McCoy had been in the running to become the J&J’s new chief executive, after its current head William Weldon announced his decision to step down last year. 

But McCoy lost the race to Alex Gorsky, who will officially take over from Weldon later this month.  

Weldon said: “Sheri has made important contributions across Johnson & Johnson throughout her career. 

European approval for prostate cancer drug Zytiga

Zytiga is an alternative to chemo for late-stage prostate cancer

Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer.

Zytiga (abiraterone acetate) is now licenced as a second-line treatment, in combination with steroid prednisone for metastatic castration-resistant prostate cancer (mCRPC), in men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

The drug is an androgen biosynthesis inhibitor, which blocks the production of testosterone, the hormone responsible for fuelling the cancer.

Xarelto receives FDA approval

Bayer J&J Xarelto (rivaroxaban)

Bayer and Johnson & Johnson’s oral blood thinner Xarelto has been approved in the US for the prevention of deep vein thrombosis after surgery.

Xarelto (rivaroxaban), a Factor Xa inhibitor, is now approved for the prevention of deep vein thrombosis that could lead to a pulmonary embolism in patients undergoing knee or hip replacement surgery in the US, where J&J holds the marketing rights to the drug.

J&J and Vertex's hep C drug Incivek approved by FDA

Vertex's Incivek (telaprevir)
Vertex said its protease inhibitor Incivek (telaprevir) would be launched in the US by the end of the week

The FDA has approved Johnson & Johnson/Vertex’s new oral hepatitis C drug Incivek.

Incivek (telaprevir), a protease inhibitor, is now licenced in the US for use in patients with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

It is approved as a first line treatment, and for previously treated patients who did not achieve a viral cure.

HIV drug Prezista recalled on TBA contamination

Johnson & Johnson has recalled 11,700 bottles of its HIV treatment Prezista after consumer reports of a mouldy smell caused by contamination with 2,4,6 tribromoanisole or TBA.

TBA contamination has been the cause of a number of J&J product recalls in the last couple of years, and has been was traced to plastic bottles and ultimately, to wood treated with a halogenated phenolic preservative which was used to manufacture pallets on which the bott

Top 5 reasons for a Class I product recall

Published on 21/04/11 at 05:25pm
William Weldon
Johnson & Johnson's William Weldon had to explain his company's recall problems to a Congressional investigation

Having to recall a pharmaceutical product because of a major quality defect or safety issue is a heart sinking moment for a drugmaker.

Even where patient safety is not at stake, a recall is an expensive undertaking, not only in direct costs but also damage to reputation and the risk of litigation.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches